Balyasny Asset Management LLC Amarin Corp Plcuk Transaction History

Balyasny Asset Management LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$1.13 - $3.69 $497,489 - $1.62 Million	440,256 New	440,256 $656,000
Q1 2022 May 16, 2022	SELL	$2.85 - $3.73 $1.04 Million - $1.37 Million	-365,973 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$3.24 - $5.18 $1.19 Million - $1.9 Million	365,973 New	365,973 $1.23 Million
Q3 2021 Nov 15, 2021	SELL	$3.94 - $5.84 $66,404 - $98,427	-16,854 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$4.26 - $6.5 $71,798 - $109,551	16,854 New	16,854 $74,000
Q2 2020 Aug 14, 2020	SELL	$4.78 - $8.26 $7.42 Million - $12.8 Million	-1,552,103 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$4.0 - $21.53 $4.57 Million - $24.6 Million	1,142,728 Added 279.14%	1,552,103 $6.21 Million
Q4 2019 Feb 14, 2020	BUY	$13.94 - $24.12 $4.59 Million - $7.94 Million	329,071 Added 409.78%	409,375 $8.78 Million
Q2 2019 Aug 14, 2019	SELL	$16.27 - $20.51 $21.7 Million - $27.4 Million	-1,333,875 Reduced 94.32%	80,304 $1.56 Million
Q3 2018 Nov 14, 2018	SELL	$2.45 - $16.27 $1.16 Million - $7.71 Million	-473,654 Reduced 25.09%	1,414,179 $23 Million
Q2 2018 Aug 14, 2018	SELL	$2.68 - $3.48 $3.29 Million - $4.27 Million	-1,226,248 Reduced 39.38%	1,887,833 $5.83 Million
Q1 2018 May 15, 2018	SELL	$2.99 - $4.44 $1.09 Million - $1.61 Million	-363,406 Reduced 10.45%	3,114,081 $9.37 Million
Q4 2017 Feb 14, 2018	BUY	$3.06 - $4.09 $2.24 Million - $2.99 Million	732,121 Added 26.67%	3,477,487 $13.9 Million
Q3 2017 Nov 14, 2017	BUY	$3.03 - $3.72 $8.32 Million - $10.2 Million	2,745,366	2,745,366 $9.61 Million

176

65.1M

258K

98K

Ticker AMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 403,206,016
Market Cap $222M
Description
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.